Phase 1, 2 and 3 Trials: — What the Numbers Mean for You

The concern is understandable, and it has a direct answer: no. You are a participant with rights protected by Indian law and international ethical standards. Every trial in India must be approved by the Central Drugs Standard Control Organisation and reviewed by an Independent Ethics Committee before anyone is enrolled. You receive more frequent monitoring than in standard care, you are told in full what you will receive before you agree, and you can leave at any point without your standard care being affected. The treatment being tested in phase 2 and 3 trials has already passed earlier research stages. The ethical oversight process exists precisely because this concern is taken seriously.

This is the fear most families bring into the conversation. In most cancer trials, a pure placebo — an inactive treatment given instead of any real medicine — is not used. Where a comparison is needed, you are typically compared against the current best standard treatment, so one group receives the new drug and the other receives the treatment already known to work. A placebo-only arm is used only when no proven standard treatment exists for your specific situation, and the consent form must state this clearly before you agree. Ask the trial team directly: is there a placebo arm, and could I be assigned to it? The answer must be in writing before you sign.

The experimental treatment itself is provided at no cost to you — that is standard across trials in India. Routine care costs, such as standard medicines or scans that would be part of ordinary treatment, may still apply depending on your insurance or public health coverage. Travel and accommodation for extra visits varies: some trials include support for this, some do not. Ask the trial coordinator three specific questions before you decide: what is covered, what is not, and whether a participant support fund exists. The answer may be more favourable than you expect, and not asking means not knowing.

Yes, at any point, without giving a reason. Participation is voluntary from the first visit to the last. If you withdraw, your treating team's responsibility to provide the best available standard care does not change. The one thing that cannot be reversed is data already collected — it may remain in the trial's record — but your continued participation is always your choice. If you are unsure whether to continue, speak to your oncologist or the trial coordinator rather than simply stopping, because a safe withdrawal process may protect you better than leaving without notice.

Ask your oncologist at your next appointment. Trials open and close continuously, and availability changes from month to month — what was not open recently may be open now. Ask specifically for your cancer type and stage, because eligibility criteria vary between studies. If no trial is currently open for your situation, ask whether a compassionate use programme or expanded access pathway exists — those are separate routes that sometimes make a treatment available before it is fully approved. The question is always worth asking, and asking it does not commit you to anything.